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All antiretroviral drugs are eventually used in pregnant
women, either as prevention of mother-to-child transmis-
sion (PMTCT), or as long-term therapy for the woman's
own health. Yet, pregnancy data is lacking for recent
drugs. Four types of pharmacologic issues should be
addressed:
1) Does PK/PD change during pregnancy due to physio-
logical factors (absorption, plasma volume, plasma pro-
teins such as albumin and alpha acid glycoprotein,
cytochrome induction), and can this lead to reduced effi-
cacy? Plasma concentrations are decreased during the 3d
trimester for several protease inhibitors (PIs). This has led
to 2 strategies, increasing the dose or performing thera-
peutic drug monitoring, however there is debate as to
whether such measures are useful when maternal viral
replication is under control.
2) Does the drug penetrate into the genital tract, and does
this play a role in prevention of transmission? Preliminary
data shows that the penetration of drugs into the genital
tract differs widely between drugs, and is very poor for
some PIs. Since one of the mechanisms of MTCT is vertical
transmission, and since viral replication in the vaginal
compartment can persist despite undetectable plasma
HIV RNA, there is concern as to whether low intravaginal
drug levels may lead to an increased transmission risk,
especially during vaginal delivery.
3) Does it cross the placenta, and what are the potential
benefits and risks of fetal exposure? For the fetus, placen-
tal transfer may either be harmful because of toxicity or
protective (PrEP). Most NRTIs diffuse across the placenta,
the fusion inhibitor enfuvirtide does not, and there are
wide differences between the various PIs. A number of fac-
tors are known to limit drug transfer (some of which are
unique to the placenta), including molecular size (imper-
meable >1000 kDa), low lipid solubility of drug, pKa, low
protein binding, low placental blood flow, placental fixa-
tion, placental metabolism, fetal acidosis. Efflux pumps
such as P-glycoprotein (MDR1) present in the trophoblast
are involved in protecting the fetus from xenobiotics in
the maternal compartment. They play an important role
in decreasing transfer of PIs to the fetus. Genetic polymor-
phisms may account for inter-individual differences.
Thus, placental transfer cannot be entirely predicted from
the physico-chemical properties of the drug, nor from its
transfer across other barriers. Several methods can be used
to determine placental transfer: clinical data (sampling at
delivery for cord blood/maternal blood ratio), animal
models, in vitro models, ie. cell cultures, placental tissue
slices, and the ex vivo human perfused cotyledon. The per-
fused cotyledon model, which determines a clearance
index, is generally predictive. Clinical data must be inter-
preted cautiously because only a single paired cord/mater-
nal sample is available, and the ratio can change
according to timing of delivery after the last administra-
tion of the drug. Population pharmacokinetics allows for
more accurate modeling with this type of data.
4) Is it metabolized by fetus, and how does this influence
its toxicities? Metabolism differs from adults due to
immaturity of fetal CYP3A (CYP3A7), as well as excretion
in the urine and gut. Little is known about the clearance
of drugs and metabolites from the fetus back through the
placenta. Thus, consequences on the fetus cannot be pre-
dicted simply from placental transfer.
In conclusion, placental transfer differs between ARVs and
is influenced by many factors. Poor placental transfer may
be an advantage, in order to avoid toxicity to the fetus, or
a disadvantage for PrEP. In order to help clinicians and
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patients to choose the optimal regimen, placental transfer
should be evaluated as part of the licensing procedure for
medications.Page 2 of 2
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